"Thrombopoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humoral factor that stimulates the production of thrombocytes (BLOOD PLATELETS). Thrombopoietin stimulates the proliferation of bone marrow MEGAKARYOCYTES and their release of blood platelets. The process is called THROMBOPOIESIS.
| Descriptor ID |
D013926
|
| MeSH Number(s) |
D12.644.276.374.410.240.750 D12.776.395.240.750 D12.776.467.374.410.240.750 D23.529.374.410.240.750
|
| Concept/Terms |
Thrombopoietin- Thrombopoietin
- Megakaryocyte Colony Stimulating Factor
- Megakaryocyte Growth and Development Factor
- Thrombocytopoietin
- mpl Ligand
- Ligand, mpl
- Myeloproliferative Leukemia Virus Oncogene Ligand
- Thrombocytopoiesis-Stimulating Factor
- Thrombocytopoiesis Stimulating Factor
- c-mpl Ligand
- Ligand, c-mpl
- MGDF Factor
|
Below are MeSH descriptors whose meaning is more general than "Thrombopoietin".
Below are MeSH descriptors whose meaning is more specific than "Thrombopoietin".
This graph shows the total number of publications written about "Thrombopoietin" by people in this website by year, and whether "Thrombopoietin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Thrombopoietin" by people in Profiles.
-
A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK. Br J Haematol. 2022 01; 196(2):351-355.
-
A Novel Use of Romiplostim for SARS-CoV-2-induced Thrombocytopenia. J Pediatr Hematol Oncol. 2021 08 01; 43(6):e788-e790.
-
Clinical applications of thrombopoietin silencing: A possible therapeutic role in COVID-19? Cytokine. 2021 10; 146:155634.
-
COVID-19 induces a hyperactive phenotype in circulating platelets. PLoS Biol. 2021 02; 19(2):e3001109.
-
Does COVID-19 Provide a Clue for Thrombosis in ITP? Semin Thromb Hemost. 2021 06; 47(4):463-466.
-
Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists. Thromb Haemost. 2019 Apr; 119(4):645-659.
-
Thrombopoietin could protect cerebral tissue against ischemia-reperfusion injury by suppressing NF-?B and MMP-9 expression in rats. Int J Med Sci. 2018; 15(12):1341-1348.
-
Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology (Oxford). 2018 Aug 01; 57(8):1432-1438.
-
Thrombopoietin mimetics for patients with myelodysplastic syndromes. Cochrane Database Syst Rev. 2017 09 30; 9:CD009883.
-
Immune thrombocytopenia - in defence of the platelet count. Response to Hill. Br J Haematol. 2018 07; 182(1):130-131.